Fasobegron (also known as ASP-8302) is an orally active β3-adrenergic receptor agonist developed for the treatment of overactive bladder (OAB). In preclinical studies, Fasobegron showed high selectivity and potency for human β3-adrenergic receptors, with an EC₅₀ of around 3.3 nM in cAMP accumulation assays. In phase 2 clinical trials, Fasobegron at doses of 50–100 mg daily significantly reduced the number of micturitions and urgency episodes in patients with OAB compared to placebo, with a tolerable safety profile. Despite promising efficacy, development was discontinued due to strategic reasons, but its bioactivity data support its potential as a β3 agonist capable of relaxing detrusor smooth muscle and improving bladder storage symptoms.
MedKoo Cat#: 319888
Name: Fasobegron
CAS#: 643094-49-9
Chemical Formula: C24H24ClNO4
Exact Mass: 425.1394
Molecular Weight: 425.91
Elemental Analysis: C, 67.68; H, 5.68; Cl, 8.32; N, 3.29; O, 15.03
The following data is based on the product molecular weight 425.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
